Precision sedation with novel single syringe multimodal opioid or non-opioid 6–2-2 mixtures
Authors' conclusion
Adjusted for age and weight, the bolus dose of the 6-2-2 mixture met the sedation requirements for ocular blocks in most patients with favorable outcomes and minimal airway or hemodynamic compromise regardless of which mixture was used.
Study context
- Population
- Adults undergoing ophthalmic surgery with ocular blocks and MAC, university outpatient surgical center
- Participants
- 1,376 adults
- Exposure
- Single-syringe 6-2-2 mixtures: 6 opioid-based vs non-opioid
- Outcome
- Sedation for ocular blocks
Methodological detailssingle-centre, Bolus dose by age and weight (adjusted weight if body mass index (BMI) >25); ocular blocks at moderate sedation
- Single-centre
- Bolus dose by age and weight (adjusted weight if BMI >25); ocular blocks at moderate sedation
Main finding
As reported in the abstract
No pain during ocular blocks, all patients (except KE6-2-2 without K10, bolus only)
91 %-98 %
No head movement, all patients (except KE6-2-2 without K10, bolus only)
98-99 %
Readiness time, opioid groups
46-51 s
Readiness time, non-opioid groups
36- 43 s
Observational data: associations, not effects.
Safety
Apnea and oxygen desaturation
- No apnea, opioid groups
- 97 %-99 %
- No oxygen desaturation, opioid groups
- 88 %-94 %
- No apnea, non-opioid groups
- 99 %
- No oxygen desaturation, non-opioid groups
- 96 %
HR and blood pressure (BP)
- HR and BP decrease, opioid groups
- <10 %
- Nearly no change in HR and BP in the non-opioid groups
Original publication
Precision sedation with novel single syringe multimodal opioid or non-opioid 6–2-2 mixtures. J Clin Anesth. Published 7 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →